Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
4.920
-0.830 (-14.43%)
Jul 30, 2026, 4:00 PM EDT - Market closed

APUS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
18.4710.281.280.650.270.53
Research & Development
2.661.63-0.10.370.49
Total Operating Expenses
21.1411.911.280.750.641.02
Operating Income
-21.14-11.91-1.28-0.75-0.64-1.02
Interest Income
0.120.1100.01--
Interest Expense
-1-0.28-0.12-0.04-0.03-0.01
Other Non-Operating Income (Expense)
0.036.09----
Total Non-Operating Income (Expense)
-19.845.91-0.11-0.03-0.03-0.01
Pretax Income
-40.97-6-1.39-0.78-0.67-1.03
Net Income
-40.97-6-1.39-0.78-0.67-1.03
Net Income to Common
-40.97-6-1.39-0.78-0.67-1.03
Net Income Growth
------
Shares Outstanding (Basic)
111000
Shares Outstanding (Diluted)
111000
Shares Change
-37.68%71.89%19.55%--
EPS (Basic)
-27.70-5.50-1.80-1.70-1.82-2.60
EPS (Diluted)
-27.70-5.50-1.80-1.70-1.82-2.60
EPS Growth
------
Free Cash Flow
-11.31-8.98-0.73-0.63-0.45-0.82
Free Cash Flow Growth
------
Free Cash Flow Per Share
-8.86-8.26-0.93-1.37-1.17-2.14
EBITDA
-21.14-11.91-1.28-0.75-0.64-1.02
EBIT
-21.14-11.91-1.28-0.75-0.64-1.02
SEC Filings: 10-K · 10-Q